Compound details
3-methyl-4-({3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyloxy)methyl]oxan-2-yl}oxy)octanoic acid
| Compound ID | CDAMM00204 |
|---|---|
| Common name | 3-methyl-4-({3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyloxy)methyl]oxan-2-yl}oxy)octanoic acid | IUPAC name | 3-methyl-4-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxan-2-yl]oxyoctanoic acid |
| Molecular formula | C22H32O12 |
| Retention time | 47.23 |
|---|---|
| Adduct | [M+NH4]+ |
| Actual mz | 506.224 | Theoretical mz | 506.223 |
| Error | 1.2 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.0823 |
| Inchi key | PCVSDYZWDASYAF-WOBSCQHONA-N |
|---|---|
| Smiles | CCCCC(C(C)CC(=O)O)OC1C(C(C(C(O1)COC(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O |
| Superclass | Lipids and lipid-like molecules |
| Class | Fatty Acyls |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P05121 | SERPINE1 | Plasminogen activator inhibitor-1 | T15556 | SEA |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SEA |
| P16109 | SELP | P-selectin | T10965 | SEA |
| P14151 | SELL | Leukocyte adhesion molecule-1 | T60526 | SEA |
| Q9NUW8 | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | T33492 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| P20916 | MAG | Myelin-associated glycoprotein (by homology) | T95286 | SEA |
| P04637 | TP53 | Tumour suppressor p53/oncoprotein Mdm2 | T15739 | SEA |
| Q99417 | MYCBP | MYCBP messenger RNA | T37298 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T15556 | DI0037 | Asthma | [ICD-11: CA23] | P05121 | SERPINE1 |
| T15556 | DI0405 | Thrombosis | [ICD-11: DB61-GB90] | P05121 | SERPINE1 |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T10965 | DI0088 | Circulatory system disease | [ICD-11: BE2Z] | P16109 | SELP |
| T10965 | DI0381 | Sickle-cell disorder | [ICD-11: 3A51] | P16109 | SELP |
| T60526 | DI0037 | Asthma | [ICD-11: CA23] | P14151 | SELL |
| T60526 | DI0088 | Circulatory system disease | [ICD-11: BE2Z] | P14151 | SELL |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T95286 | DI0219 | Ischaemic/haemorrhagic stroke | [ICD-11: 8B20] | P20916 | MAG |
| T15739 | DI0233 | Lip/oral cavity/pharynx neoplasm | [ICD-11: 2B6E] | P04637 | TP53 |
| T15739 | DI0323 | Ovarian dysfunction | [ICD-11: 5A80] | P04637 | TP53 |
| T15739 | DI0413 | Transplant rejection | [ICD-11: NE84] | P04637 | TP53 |
| T37298 | DI0235 | Liver cancer | [ICD-11: 2C12] | Q99417 | MYCBP |